Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
22
06
2021
accepted:
10
08
2021
pubmed:
5
9
2021
medline:
27
10
2021
entrez:
4
9
2021
Statut:
ppublish
Résumé
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml
Identifiants
pubmed: 34480127
doi: 10.1038/s41591-021-01499-z
pii: 10.1038/s41591-021-01499-z
pmc: PMC8516650
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Placebos
0
Receptors, Urokinase Plasminogen Activator
0
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1752-1760Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care 24, 187 (2020).
doi: 10.1186/s13054-020-02897-4
Azam, T. U. et al. Soluble urokinase receptor (suPAR) in COVID-19-related AKI. J. Am. Soc. Nephrol. 31, 2725–2735 (2021).
doi: 10.1681/ASN.2020060829
Renieris, G. et al. IL-1 mediates tissue specific inflammation and severe respiratory failure in Covid-19: clinical and experimental evidence. Preprint at medRxiv https://doi.org/10.1101/2021.04.09.21255190 (2021).
Rodrigues, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 218, e20201707 (2021).
doi: 10.1084/jem.20201707
Kyriazopoulou, E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10, e66125 (2021).
doi: 10.7554/eLife.66125
Manson, J. J. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2, e594–e602 (2020).
doi: 10.1016/S2665-9913(20)30275-7
Webb, B. J. et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2, e754–e763 (2020).
doi: 10.1016/S2665-9913(20)30343-X
Caricchio, R. et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann. Rheum. Dis. 80, 88–95 (2021).
doi: 10.1136/annrheumdis-2020-218323
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021).
doi: 10.1016/S0140-6736(21)00676-0
Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).
doi: 10.1056/NEJMoa2100433
Guimarães, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 385, 406–415 (2021).
doi: 10.1056/NEJMoa2101643
Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive ventilation in patients hospitalized with severe COVID-19. A randomized clinical trial. JAMA 236, 230–239 (2021).
doi: 10.1001/jama.2021.9508
Jamilloux, Y. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun. Rev. 19, 102567 (2020).
doi: 10.1016/j.autrev.2020.102567
Bozzi, G. et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J. Allergy Clin. Immunol. 147, 561–566 (2021).
doi: 10.1016/j.jaci.2020.11.006
Cavalli, G. et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 3, e253–e261 (2021).
doi: 10.1016/S2665-9913(21)00012-6
Kooistra, E. J. et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit. Care 24, 688 (2020).
doi: 10.1186/s13054-020-03364-w
Cauchois, R. et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc. Natl Acad. Sci. USA 117, 18951–18953 (2020).
doi: 10.1073/pnas.2009017117
Pontali, E. et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J. Allergy Clin. Immunol. 147, 1217–1225 (2021).
doi: 10.1016/j.jaci.2021.01.024
Huet, T. et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2, e393–e400 (2020).
doi: 10.1016/S2665-9913(20)30164-8
CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med. 9, 295–304 (2021).
doi: 10.1016/S2213-2600(20)30556-7
Balkhair, A. et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int. J. Infect. Dis. 103, 288–296 (2021).
doi: 10.1016/j.ijid.2020.11.149
Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 384, 1503–1516 (2021).
doi: 10.1056/NEJMoa2028700
Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384, 20–30 (2021).
doi: 10.1056/NEJMoa2030340
Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 383, 2333–2344 (2020).
doi: 10.1056/NEJMoa2028836
Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern. Med. 181, 24–31 (2021).
doi: 10.1001/jamainternmed.2020.6615
Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992–1000 (2020).
doi: 10.1016/j.chom.2020.04.009